Drug intelligence / Profile preview

DLQ04

Development stage: Preclinical
Lead developer: Dermaliq Therapeutics
Administration: Topical

Overview

DLQ04 is an investigational topical drug candidate being developed by Dermaliq Therapeutics, in collaboration with DEBRA Research, for the treatment of epidermolysis bullosa (EB). The drug is formulated using Dermaliq's proprietary hyliQ® technology platform, which is designed to enable touchless, non-contact delivery of active therapeutic compounds directly into fragile, sensitive, or disease-affected skin without causing mechanical trauma or friction. DLQ04 is currently in preclinical development, aiming to address key symptoms of EB such as wound healing, itch relief, and the prevention of new skin lesions.

Beyond the preview

Go deeper on DLQ04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DLQ04.

Explore the full profile